CS2009 is an investigational PD-1/VEGFA/CTLA-4 trispecific antibody developed by CStone for solid tumors. Clinical development has progressed through Phase I/II with more than 200 enrolled patients and ongoing preparation for Phase III multi-regional studies. The agent remains unapproved and in clinical development.
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06741644 |
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
